HC Wainwright Has Bearish Estimate for AxoGen Q2 Earnings

Key Points

• HC Wainwright lowered its Q2 2026 EPS estimate for AxoGen to ($0.02) from ($0.01) but kept a "Buy" rating and a $50 price target, projecting FY2026 EPS of ($0.32) and FY2027 EPS of $0.44 (a return to profitability).
• AxoGen missed EPS expectations, reporting $0.07 per share vs. a $0.12 consensus, while beating revenue estimates with $61.46 million, signaling top-line strength amid margin pressure.
• Analyst sentiment is largely positive—nine Buy ratings vs. two Sell—with a consensus target of $46.50 and shares trading in the low $40s (market cap ~ $2.27B).

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Investment analysts at HC Wainwright dropped their Q2 2026 EPS estimates for AxoGen in a research note issued to investors on Wednesday, April 29th. HC Wainwright analyst Y. Chen now expects that the medical equipment provider will post earnings of ($0.02) per share for the quarter, down from their previous estimate of ($0.01). HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for AxoGen's current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for AxoGen's Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at ($0.32) EPS, Q1 2027 earnings at $0.05 EPS, Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at $0.14 EPS, Q4 2027 earnings at $0.16 EPS and FY2027 earnings at $0.44 EPS.

AxoGen (NASDAQ:AXGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. The firm had revenue of $61.46 million for the quarter, compared to analyst estimates of $57.85 million.

Several other equities analysts also recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of AxoGen from $45.00 to $50.00 and gave the company a "buy" rating in a report on Wednesday, April 29th. Wells Fargo & Company boosted their price target on shares of AxoGen from $40.00 to $48.00 and gave the company an "overweight" rating in a report on Wednesday, April 29th. Citigroup reissued an "outperform" rating on shares of AxoGen in a report on Wednesday, April 29th. Zacks Research downgraded shares of AxoGen from a "hold" rating to a "strong sell" rating in a report on Monday, April 27th. Finally, Wall Street Zen downgraded shares of AxoGen from a "buy" rating to a "hold" rating in a report on Saturday. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $46.50.

AxoGen Stock Performance

Shares of AXGN opened at $42.63 on Tuesday. AxoGen has a 1 year low of $9.22 and a 1 year high of $45.83. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -66.61 and a beta of 1.17. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10. The firm has a fifty day moving average of $33.65 and a 200-day moving average of $30.58.

Insider Buying and Selling

In other AxoGen news, insider Erick Wayne Devinney sold 5,221 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $32.84, for a total transaction of $171,457.64. Following the sale, the insider owned 262,781 shares in the company, valued at approximately $8,629,728.04. The trade was a 1.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.78% of the company's stock.

Institutional Trading of AxoGen

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC raised its holdings in AxoGen by 1.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 21,473 shares of the medical equipment provider's stock worth $703,000 after buying an additional 371 shares during the period. Arax Advisory Partners raised its holdings in AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider's stock worth $34,000 after buying an additional 819 shares during the period. Brooklyn Investment Group raised its holdings in AxoGen by 4.2% during the 4th quarter. Brooklyn Investment Group now owns 20,568 shares of the medical equipment provider's stock worth $688,000 after buying an additional 823 shares during the period. MCF Advisors LLC acquired a new stake in AxoGen during the 4th quarter worth about $30,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in AxoGen by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider's stock worth $466,000 after buying an additional 1,057 shares during the period. Institutional investors and hedge funds own 80.29% of the company's stock.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.